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Potential utility of p63 expression in differential 
diagnosis of non-small-cell lung carcinoma 
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 Background: P63 is a gene located in chromosome 3q27-29, which has been implicated in regulation of stem cell commitment 
and promotion of squamous differentiation in various tissues. The aim of this study was to investigate wheth-
er there was a correlation between p63 expression, differential diagnosis of lung carcinoma, and prognosis.
 Material/Methods: Immunohistochemical expression of p63 in 62 lung carcinomas was investigated and mRNA analysis using 
RT-PCR method was done in 6 selected cases.
 Results: When cases were evaluated for p63 staining, 24 of 25 (96%) squamous cell carcinomas were strongly posi-
tive. Six of 20 adenocarcinomas (25%) and 1 (100%) large cell carcinoma (except neuroendocrine carcinoma) 
were mildly positive. p63 staining was statistically significant in favor of squamous cell carcinoma than other 
tumors (p<0.001). Forty percent of squamous cell carcinomas had squamous carcinoma in situ, whereas ade-
nocarcinomas had none. There was a significant statistical difference between squamous cell carcinoma and 
adenocarcinoma (p=0.002). p63 was strongly positive in all of 12 squamous carcinoma in situ cases. In 6 cas-
es where mRNA analysis was performed by RT-PCR method, DNp63 was strongly positive in 3 squamous cell 
carcinomas, mildly positive in 1 adenocarcinoma, and negative in 1 carcinoid tumor. TAp63 was strongly posi-
tive in non-tumoral lung tissue but negative in all tumors, except 1 squamous cell carcinoma.
 Conclusions: Our data suggest that poorly differentiated squamous cell carcinoma had strong and widespread staining for 
immunohistochemical expression of p63. Therefore, p63 can be a useful marker in differentiating squamous 
cell carcinoma from poorly differentiated adenocarcinoma and squamous cell carcinoma from large cell neu-
roendocrine carcinoma.
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Background
Non-small cell lung carcinomas are a heterogeneous group of 
tumors having poor prognosis. Eighty percent of lung cancer 
cases are at an inoperable advanced stage at the time of diag-
nosis [1,2]. A wide range of therapies, including targeted ther-
apy, are being used for treatment. Generally, histological diag-
nosis must be done on bronchoscopic small biopsy specimens 
[3]. It frequently shows histological heterogeneity, varying in 
appearance and differentiation from one microscopic field to 
another and from one histological section to the next (2). Small 
specimens may not show differentiation when the tumor is 
excised. During morphologic evaluation, usually supported by 
immunohistochemical markers in routine work, 30–40% of tu-
mors are accurately classified in small biopsy specimens, es-
pecially when the tumor is a poorly differentiated or is an un-
differentiated carcinoma [4].
Defined for the first time in 1998, P63 is a gene located in chro-
mosome 3q27-29, containing 15 exons and at least 6 protein 
isoforms [5,6]. P63 has 6 different isotypes that have been 
identified to date. It is suggested that the proteins coded from 
these isotypes have biological functions differing from one 
another. P63 isotypes are basically generated by 2 promoters 
(TA and DN) and 3 alternative splice regions (a, b, and c) that 
are located in the carboxy terminal region [7–10]. There is a 
transactivation region at the amino terminal in TAp63, which 
is one of the two most important isotypes, whereas there is 
no transactivation region at the amino terminal in DNp63, the 
other important isotype. In this way, the TAp63 isotype acti-
vates the targeted genes of p53 (p21waf1/cip1, mdm2 and 
bax) to stop the cell cycle and makes the cell turn to apopto-
sis. The DNp63 isoform, by contrast, acts “dominant-negative” 
to suppress this transcriptional activation and trigger cell pro-
liferation [7,10–12].
Recently, p63 has been implicated in regulation of stem cell com-
mitment and promotion of squamous differentiation in various 
tissues. Experimental studies have shown that in the process 
of embryonic development, p63 expression is needed during 
epidermal morphogenesis that involves formation of extrem-
ities and structures such as tooth, hair, mammary, and pros-
tate glands, and sweat and lacrimal glands [13]. Its basic role 
is to form the squamous epithelial phenotype by suppressing 
mesenchymal cell characteristics [14]. Transformation of early 
stem cells into basal cells is significant for the development of 
the normal tracheobronchial pseudo-stratified epithelium and 
the squamous epithelium of the esophagus [15]. That is why 
it is especially expressed in areas where there is an epithelial-
mesenchymal interaction. In animals with deficient p63, there 
are problems in structures that require a proper epithelial-mes-
enchymal interaction during their morphogenesis, and such 
animals have been shown to die a short time after birth [14].
In adults, p63 has an important role in securing stem cell pop-
ulation in squamous and other multi-layered epithelia. While 
bronchial reserve cells are intensely stained immunohisto-
chemically in normal lung tissue, no staining is seen in ciliat-
ed cells, goblet cells, alveolar epithelial cells, or non-epithelial 
cells. Positive cells in terminal bronchioles have a dispersed 
distribution. Staining is also seen in myoepithelial cells in sub-
mucosal bronchial glands. There is staining in squamous meta-
plasia and this staining is observed in many cell sequences 
[16,17]; this is an indication that p63-positive reserve cells can 
build the squamous epithelium in lungs when necessary [17]. 
In some lung cancers, p63 is expressed excessively. However, 
p53 positivity rates for subtypes may differ in the results of 
various studies, although there are some similarities among 
them [2,16–18].
In this project, we analyzed p63 expression in non-small cell 
carcinoma and preinvasive lesions (squamous carcinoma in 
situ and atypical adenomatous hyperplasia) of non-small cell 
carcinoma. Overall data was evaluated to search for any effect 
on the differential diagnosis of non-small cell lung carcinoma 
and clarification of histogenesis of lung tumors. In a group of 
chosen cases, the isotype-specific gene expressions of TAp63 
and DNp63 at mRNA level were analyzed in lung tumor tis-
sue. Results obtained may serve to further clarify lung tumor 
pathogenesis and to help differentiate diagnosis in these cases.
Material and Methods
A total of 62 archival, routinely processed, formalin-fixed and 
paraffin-embedded surgical pathology specimens from lobec-
tomy and pneumonectomy specimens for primary lung carci-
noma were acquired from the pathology archives of Pamukkale 
University Hospital, Denizli, Turkey. Information on standard 
identities of patients, preoperative stages of tumors, method 
of treatment, follow-up periods, and disease outcomes (data 
on disease-free survival, relapses, and cancer-related deaths) 
was obtained from the records. All cases of tissue samples were 
retrieved, reviewed, and classified according to the 2004World 
Health Organization classification of lung tumors [19] (Table 1).
Immunohistochemistry
Expression of p63 in 62 lung carcinomas was investigated im-
munohistochemically. Sections expressing the most representa-
tive tumor were chosen for further immunohistochemical anal-
ysis. Five-micron sections of formalin-fixed, paraffin-embedded 
tissue sections were tested for the presence of immunohisto-
chemically detectable antigens with anti-p63 antigen (Clone 
4A4, BioGenex, USA). Tissue sections were processed with the 
standard streptavidin-biotin-immunoperoxidase method on an 
automatic Ventana-Nexes immunostainer (Ventana Medical 
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Systems, Tucson, Arizona). Nuclear p63 staining was evaluat-
ed using a semi-quantitative and subjective grading system 
that considered both the intensity of staining and the propor-
tion of tumor cells in a tissue section showing an unequivo-
cal positive reaction. Staining percentage of nuclear staining 
area was graded as 0 (0–10 tumor cells positive), 1 (positive 
staining in 10–44% of the tumor cells), or 2 (positive staining 
in 45% to 100% of the tumor cells).
mRNA	analysis	of	TAp63	and	DNp63	using	RT-PCR
Specific gene expressions of TAp63 and DNp63 isotypes were 
analyzed using RT-PCR in a group of 6 tumor and adjacent 
non-tumor lung tissues. Total RNA was isolated from paired 
fresh-frozen tumor and non-tumor lung tissues using Tri-
Reagent (Sigma). Extracted RNA was precipitated with isopro-
panol, and then assessed for integrity of ribosomal RNA by 
agarose gel electrophoresis. Multiplex RT-PCR was performed 
using the OneStep RT-PCR kit (Cat # 210212, Qiagen) accord-
ing to the manufacturer’s protocol. Appropriate cycles were 
chosen to ensure the termination of PCR amplification before 
reaching a stable stage in each reaction. Gene expression was 
presented as the yield of PCR products from target sequences 
relative to the yield of PCR products from the GAPDH house-
keeping gene. Multiplex OneStep RT-PCR reaction parameters 
used for TAp63/GAPDH and DNp63/GAPDH were as follows: re-
verse transcription at 50°C for 30 min, initial activation of DNA 
polymerase enzyme at 95°C for 15 min, followed by 35 cycles 
of 94°C for 1 min, 62°C for 1 min, 72°C for 1 min, and a final 
extension of 72°C for 10 min. PCR products were subjected to 
electrophoresis on a 4% ethidium bromide (Et-Br)-stained MS 
agarose (Roche) gel and visualized under UV for the control of 
their specificity and integrity. PCR primers are listed in Table 2.
Results
The mean disease-free survival time of the 62 patients who 
were included in the study was 15.8±10.2 months (minimum 1 
month, maximum 38 months). The disease relapsed in 10.5% 
of the patients and 82.5% of the patients on follow-up were 
still alive at the end of the follow-up period.
Table 1. Histopathological types of cases.
Histopathological types
Number of patients 
(n)
%
Squamous cell carcinoma 24 38.7
Adenocarcinoma 20 32.3
Carcinoid tumor 5 8.1
Large cell neuroendocrine 
carcinoma
3 4.8
Sarcomatoid carcinoma 3 4.8
Atypical carcinoid tumor 1 1.6
Large cell carcinoma, not 
specified
1 1.6
Adenosquamous carcinoma 1 1.6
Mukoepidermoid carcinoma 1 1.6
Squamous cell carcinoma 
+ large cell neuroendocrine 
carcinoma
1 1.6
Adenocarcinoma + carcinoid 
tumor
1 1.6
Adenocarcinoma + squamous 
cell carcinoma
1 1.6





















 40–65 41 66.1
 >65 17 27.4
Sex
 Male 58 93.5
 Female 4 6.5
Localization
 Right 39 62.9
 Left 23 37.1
Metastasis of lymph node
 Yes 19 30.6
 No 43 69.4
Table 3. Clinicopathological factors.
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According to the AJCC TNM staging system, the majority of 
the cases were at Stage IB (38.7%), Stage IA (17.7%), Stage IIB 
(17.7%), and Stage IIIA (22.6%), and only 3.2% of them were 
at Stage IIIB. The sizes of tumors ranged between 1.9 and 8 
cm, with a mean size of 3.8±1.3 cm. Most of the cases had a 
tumor size of T2 (58.1%). The clinicopathologic findings of the 
cases are summarized in Table 3.
When cases were evaluated for p63 staining by immunohis-
tochemistry, 24 of 25 (96%) squamous cell carcinomas were 
strongly positive (Figure 1). Six of 20 adenocarcinomas (25%) 
and 1 (100%) large cell carcinoma (except neuroendocrine car-
cinoma) were mildly positive. P63 staining was statistically sig-
nificant in favor of squamous cell carcinoma as compared to 
other tumors (p<0.001).
In cases with squamous cell carcinoma, we noticed that in 
well-differentiated areas, p63 staining was stronger on the 
peripheries of tumor islands, but the extent and intensity of 
staining decreased towards the center. In poorly differentiat-
ed areas, on the other hand, the intensity of staining in the 
center and on the peripheries were similar and staining was 
more intense and widespread than in well-differentiated areas 
(Figure 1). When 5 cases of adenocarcinoma that were stained 
with p63 were assessed in terms of different subtypes (aci-
nar, papillary, solid, nonmucinous bronchoalveolar, and signet 
ring area), staining was found to be between 2–30%. In 10 
cases of adenocarcinoma that had solid areas, there was mild 
staining in 5 of these solid areas (2% in 3 cases, 5% in 1 case, 
and 18% in 1 case) and there was no staining in the other 5.
Forty percent of squamous cell carcinomas had squamous 
carcinoma in situ (Figure 2), whereas adenocarcinomas had 
none. There was a significant statistical difference between 
squamous cell carcinoma and adenocarcinoma in p63 stain-
ing (p=0.002). P63 was strongly positive in all of 12 squamous 
carcinoma in situ cases, but in 83.3% of atypical adenomatous 
hyperplasia, p63 was negative.
In 6 cases in which mRNA analysis was performed by the 
OneStep multiplex RT-PCR method, DNp63 was strongly posi-
tive in 3 (3/3) squamous cell carcinoma cases, mildly positive 
in 1 (1/1) adenocarcinoma case, and negative in 1 carcinoid 
tumor case (Figure 3A). TAp63 was strongly positive in non-
tumoral lung tissue, but was negative in all tumors, except for 
1 squamous cell carcinoma (Figure 3B).
The mean follow-up period was 32±3 months for the 22 cas-
es that showed no staining with p63, 16±3 months for those 
whose p63 index showed low staining, and 37±3 months for 
cases involving high staining. Survival rates were 81.82% in 
the group that had no staining with p63, 66.67% in the group 
Figure 1. (A, B). Decreased expression pattern of p63 in 
well differentiated squamous cell carcinoma 
particularly at central of squamous island (H&E, p63 
immunohistochemistry ×100). (C) Expression pattern of 
p63 in poorly differentiated squamous cell carcinoma 
(p63 immunohistochemistry ×200).
Figure 2. (A) Squamous metaplasia (H&E ×100). (B) Squamous 
metaplasia (p63 immunohistochemistry ×100). 
(C) Displasia (H&E ×100). (D) Displasia (p63 
immunohistochemistry ×100). (E) Squamous carcinoma 
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whose p63 index showed low staining, and 88.46% in the 
group that showed high staining. This relationship was not 
found statistically significant (p>0.05).
In multi-variation analysis, the effect of age, largest tumor 
size, sex, TNM stage, tumor differentiation, distant metasta-
sis, lymph node metastasis, angiolymphatic invasion, pleu-
ral invasion, neural invasion, stromal reaction type, presence 
of endobronchial lesion, presence of distant organ metasta-
sis, presence of relapse, stage, tumor size, tumor localiza-
tion, and p63 antibody reactivation on the rate of surviv-
al was explored and only presence of metastasis (p<0.001) 
was found to be an independent prognostic factor in deter-
mining the prognosis.
Discussion
Male sex and advanced age are related to poor prognosis in 
stage I and II lung cancer, regardless of the histological type. 
At stage III, the worsening of general condition and an ele-
vated serum lactate dehydrogenase (LDH) level indicate poor 
prognosis [20]. No significant correlation was found in this 
study between survival and the clinico-pathologic parame-
ters of age, sex, tumor localization, presence of endobron-
chial lesion, pleural invasion, angiolymphatic invasion, neural 
invasion, nature of stromal response to tumor, stage, or p63 
expression. However, the relationship between tumor diame-
ter and survival showed that the survival rate was 95.65% in 
patients whose tumor diameter was 3 cm and shorter, but the 
rate dropped to 73.53% in tumors having a diameter longer 
than 3 cm. As another parameter, the Ts that are involved in 
the TNM classification used for staging and that assess both 
tumor diameter and the position of the tumor in the lungs as 
well as its relationship with the other organs in the medias-
tinum, were evaluated separately and the survival rates that 
were 92.86% for T1 and 87.88% for T2 went down to 50% for 
T3 and T4, and this relationship was found to be statistically 
significant by Kaplan-Meier survival analysis. There are stud-
ies in the literature that stress the effect of TNM stage of a 
tumor on prognosis in support of the findings of the present 
study [21,22].
The studies in the literature that relate to p63 expression in 
squamous cell carcinoma are in complete agreement with each 
other. As in the present study, they also reported strong p63 
positivity in squamous cell carcinoma. They have demonstrat-
ed that in well-differentiated tumors, staining is strong on the 
peripheries of the tumor mass and is weakened in the center, 
where differentiation increases and p63 positivity becomes 
stronger as tumor differentiation decreases. They have de-
scribed that there is intense staining in the centers of solid tu-
mor masses, similar to that on their peripheries [16,17,23,24]. 
Conforming with the literature, the present study also demon-
strated that cases involving moderate and poorly differentiat-
ed squamous cell carcinoma had markedly strong p63 expres-
sion immunohistochemically. As described in the literature, in 
well-differentiated areas that were seen in the form of focal 
points in these tumors, the p63 staining in the centers of tu-
mor masses was weaker (Figure 1).
Squamous carcinoma in situ is a lesion that develops in bron-
chial epithelia in the large airways; it can exist by itself or with 
invasive carcinoma and is a precursor to squamous cell carcino-
ma [25]. While squamous carcinoma in situ was found in 40% 
of the squamous cell carcinoma cases, it was not found in any 
of the adenocarcinoma cases. This finding may, in small biopsy 
materials, help interpret the biopsy in favor of squamous cell 
carcinoma by taking into consideration the presence of squa-
mous carcinoma in situ accompanying the tumor. Atypical ad-
enomatous hyperplasia is another lesion that is accepted as 
a precursor of peripheral pulmonary adenocarcinoma and is 
generally noticed incidentally and multifocally in materials re-
sected due to adenocarcinoma [25,26]. In the present study, 
atypical adenomatous hyperplasia accompanied 20% of ade-
nocarcinoma cases and 1% of squamous cell carcinoma cas-
es. Since there is no significant statistical difference between 
these 2 groups in terms of atypical adenomatous hyperpla-
sia, it is not possible for us to make a similar interpretation 
for atypical adenomatous hyperplasia.
A
B
Figure 3. (A) DNp63 and GAPDH mRNA expression ((M: Marker, 
1: AC-T, 2: AC-N, 3: Carcinoid-T, 4: Carcinoid-N 5: SCC-T, 
6: SCC-N, 7:SCC-T, 8: SCC-NT, 9: MEC-T, 10: MEC-N, 
11:SCC-T, 12:SCC-N, M:Marker) (AC: Adenocarcinoma, 
SCC: Squamous cell carcinoma, MEC: Mukoepidermoid 
Carcinoma, T: Tumor, N: Normal ). (B) TAp63 ve GAPDH 
mRNA expression (M: Marker, 1: AC-T, 2: AC-N, 3: 
Carcinoid-T, 4: Carcinoid-N 5: SCC-T, 6: SCC-N, 7: SCC-T, 
8: SCC-NT, 9: MEC-T, 10: MEC-N, 11: SCC-T, 12: SCC-N) 
(AC: Adenocarcinoma, SCC: Squamous cell carcinoma, 
MEC: Mukoepidermoid Carcinoma, T: Tumor, N: 
Normal).
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There are just a few studies in the literature on p63 expression 
in preinvasive lesions. Massion et al investigated 43 preinva-
sive squamous lesions using the in situ hybridization (FISH) 
method, reporting increased p63 gene copy numbers in high-
grade lesions involving severe dysplasia and carcinoma in 
situ and they found this amplification correlated to p63 im-
mune staining [23]. In their study including 221 cases of stage 
I non-small cell carcinoma and 57 cases of stage I-IV neuro-
endocrine carcinoma, Pelosi et al examined p63 staining in 
hyperplastic, metaplastic, and dysplastic bronchial epithelia. 
They found increasing p63 positivity in basal cell hyperplasia, 
squamous metaplasia, and mild, moderate, and severe dys-
plasia (44.9±2.8%, 62.3±6.2%, 52.6±14.5%, 65.7±9.7%, and 
76.3±4.1%, respectively) [16]. In both these studies, there 
was a distinct increase in p63 expression during the transition 
from preinvasive to invasive lesion. They reported in another 
study that they found full-layer p63 staining in an unstated 
number of areas with squamous carcinoma in situ, which ac-
companied 30 cases of squamous cell carcinoma [17]. In the 
present study, p63 was found highly positive in all (100%) of 
the 12 squamous carcinoma in situ lesions. An assessment of 
the 6 atypical adenomatous hyperplasia areas that were en-
countered in the study showed that there was mild staining 
in only 1 case (16.7%) and no staining in the other 5 cases 
(83.3%). This finding is similar to that of the study by Sheikh 
et al., who reported p63 positivity in 2 of the 5 atypical ade-
nomatous hyperplasia areas [27].
In addition to the immunohistochemical method, Massion et al. 
carried out investigations using the FISH and RT-PCR methods. 
They obtained 88% p63 positivity in squamous cell carcinoma 
using the FISH method. Using the RT-PCR method, they found 
positivity with delta-N p63-alpha and delta-N p63-beta in all 
of the squamous cell carcinoma cases and they found slight 
positivity with TA p63 in some of the squamous cell carcino-
ma cases. They found negativity with both delta-N p63 and TA 
p63 in normal lung tissue [23]. Similar to Massion’s previous 
study, we also obtained negative results in our study in squa-
mous cell carcinoma, with the exception of the positivity we 
obtained with RT-PCR in delta-N p63 (3/3) and the positivity 
we found in 1 case for TA p63. Unlike Pierre’s study, we ob-
tained a positive result with TA p63 in normal lung tissue [23].
There are inconsistent results in the literature with respect 
to immunohistochemical expression of p63 in adenocarcino-
ma. While some studies found 12%, 11%, 15.8%, and 30% 
(6, 8, 76, 78, respectively) immunohistochemical p63 positiv-
ity in adenocarcinoma, p63 was negative in adenocarcinoma 
in some other studies [2,27]. In the study by Sheikh et al (one 
of the studies that reported positivity), less than 5% staining 
was observed in 3 of the 4/33 adenocarcinoma cases stained 
with p63 positive and, by contrast, more than 80% positivity 
was found in 1 case [27]. P63 positivity was 15.8% in the 15 
adenocarcinoma cases included in the study of Pelosi et al. 
The proportion of positive cells in the cases accepted as pos-
itive has been reported to be 5.4±15.9% (16).
Massion et al reported 11% gene amplification using the FISH 
method and 18% protein expression using the immunohisto-
chemical method in adenocarcinoma cases. They also found 
that a limited number of adenocarcinoma cases they worked on 
were negative with delta-N p63-alpha, delta-N p63-beta, and 
TA p63 splice variants (23). In the present study, slight delta-N 
p63 positivity and TA p63 negativity were found in the tumor 
of a single adenocarcinoma case using RT-PCR and delta-N p63 
negativity and TA p63 positivity in normal lung parenchyma.
In their study involving 408 lung carcinoma cases, Au et al 
used in 2 different laboratories p63 antibodies of the same 
concentration and used different protocols. While the results 
in these 2 laboratories were similar for squamous cell carcino-
ma, they obtained different results in types outside this car-
cinoma. Staining was 30% in one laboratory and 8.6% in the 
other for adenocarcinoma [18]. They explained this difference, 
which occurred although they used p63 of the same concen-
tration in the same series, by citing technical differences and 
differences in the other chemicals used.
In normal neuroendocrine cells, neuroepithelial bodies, and 
neuroendocrine tumorlets, p63 negativity shows that these 
cells developed from stem cells independent of p63 (p63–, 
SK+) or that they lost p63 expression at an early stage. Pelosi 
et al concluded that because p63 positivity was found in high-
grade neuroendocrine carcinoma (45%) and especially in large-
cell neuroendocrine carcinoma, at least some of these tumors 
developed from stem cells similar to those in other non-small 
cell lung carcinomas [6]. As p63 positivity was not found in 
the present study in any of the 3 large-cell neuroendocrine 
carcinoma cases, this suggests in a similar way that not all of 
even large-cell neuroendocrine carcinomas follow the same 
development path.
The p63 positivity, which was found to be 17.5% in 57 neuro-
endocrine carcinoma cases included in another study, was re-
ported to be as follows for respective subtypes: 7/10 for large-
cell neuroendocrine carcinoma, 2/10 for small-cell carcinoma, 
1/28 for carcinoid tumors, and 0/9 for atypical carcinoid tu-
mors [16]. In the study by Au et al in 2 separate laboratories 
using p63 of the same concentration on 408 cases, different 
results were obtained in carcinoma types other than squamous 
cell carcinoma. In 1 of the laboratories, positivity was 37% in 
large-cell carcinoma, 1.9% in carcinoid tumors, 30.8% in atypi-
cal carcinoid, 50% in large-cell neuroendocrine carcinoma, and 
76.9% in small-cell carcinoma. These results show that p63 ex-
pression increases as differentiation decreases in neuroendo-
crine carcinoma. When the same cases were stained with p63 
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in the second laboratory, positivity was 23.6% in large-cell car-
cinoma, 1.7% in carcinoid tumors, 14.8% in atypical carcinoid, 
0% in large-cell neuroendocrine carcinoma, and 30.8% in small-
cell carcinoma [18]. They stressed that this difference, which 
occurred although they used p63 of the same concentration in 
the same series, was due to technical differences and differ-
ences in the other chemicals and that p63 positivity was not a 
reliable marker of p63 positivity in neuroendocrine carcinoma.
In addition to these studies reporting varying positivity in neu-
roendocrine carcinoma, there are also studies in which no stain-
ing was found. Zhang et al. reported that they found staining 
in none of the 28 small-cell neuroendocrine carcinoma cases 
[5]. Kargı et al. reported p63 positivity in the same number of 
small-cell neuroendocrine carcinoma cases [24]. There was no 
staining reported in the study by Wang et al. on 9 small-cell 
carcinoma cases and 5 carcinoid tumor cases [17].
From the 9 neuroendocrine carcinoma cases that were in-
cluded in the present study, 5 were typical carcinoid tumors, 
3 were large-cell neuroendocrine carcinomas, and 1 was an 
atypical carcinoid tumor. Staining with p63 was not found in 
any of these. In the carcinoid tumor case for which mRNA anal-
ysis was carried out for p63 using RT-PCR, a negative result 
was obtained with delta-N p63 and TA p63. However, similar 
to other tumor types, negativity was found with TA p63 and 
positivity with delta-N p63 in samples from normal lung tis-
sues of this case. These results show that p63 negativity can 
be used to verify neuroendocrine carcinoma in cases where 
there is a differential diagnosis problem in deciding between 
poorly-differentiated squamous cell carcinoma and large-cell 
neuroendocrine carcinoma.
In a study in which 5 adenosquamous carcinomas were assessed, 
p63 positivity was found in all of the cases. Positivity in the squa-
mous areas of these cases ranged between 5% and 90%, with 
more than 50% in most of them. There was positivity ranging be-
tween 0% and 20% in areas with adenocarcinoma [27]. Another 
study reported 100% p63 positivity in 5 adenosquamous carcino-
ma cases, but did not mention the distribution of such positivi-
ty between areas of adenocarcinoma and squamous areas [17]. 
In the single adenosquamous carcinoma case that appeared in 
the present study, there was moderate staining in squamous ar-
eas, but no staining was observed in areas of adenocarcinoma.
In their study investigating the effect of p63 on prognosis, 
Narahashi et al found 50% nuclear and 51% cytoplasmic p63 
positivity in adenocarcinoma [27]. From the 20 adenocarcino-
ma cases included in the present study, 6 that were stained 
with p63 showed faint staining (10–40%), similar to results in 
the literature. An examination of solid areas, which are most 
frequently confused with poorly differentiated squamous cell 
carcinoma, revealed that there was p63 positivity in 5 of the 
10 solid areas. In these 5 cases that had solid areas stained 
with p63 positive, there was slight staining in solid areas (2% 
in 3 cases, 5% in 1 case, and 18% in 1 case).
Conclusions
Our data suggest that poorly differentiated squamous cell 
carcinoma has strong and widespread immunohistochemical 
staining of p63. Therefore, p63 should be a useful marker in 
distinguishing poorly differentiated squamous cell carcinoma 
from poorly differentiated adenocarcinoma and squamous cell 
carcinoma from large cell neuroendocrine carcinoma. Our RT-
PCR results also reveal that evaluating mRNA of p63 can be 
helpful alongside immunohistochemical staining when diag-
nosis is difficult in poorly differentiated squamous cell carci-
noma, adenocarcinoma, and large-cell neuroendocrine carci-
noma. However, it should be borne in mind that because p63 
expression is also seen in squamous cell carcinoma of the 
head-neck, squamous cell carcinoma of the esophagus, tran-
sitional cell carcinoma of the urinary bladder, and in gastric 
carcinoma, p63 is not useful in distinguishing the metastasis 
of these tumors to the lungs from primary lung carcinoma.
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